Literature DB >> 18061029

Inflammation and benign prostatic hyperplasia.

J Curtis Nickel1.   

Abstract

Prostatitis, a histologic diagnosis, has evolved over the years to describe a clinical syndrome that was believed to be associated with prostatic inflammation. Similarly, benign prostatic hyperplasia (BPH), another histologic diagnosis, has evolved to describe a clinical syndrome believed to be associated with prostatic enlargement. Recent explorations of the interrelationships between these prostate-associated histologic and clinical conditions have generated much interest and excitement. This article describes these relationships and their impact on the management of, in particular, BPH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18061029      PMCID: PMC2198849          DOI: 10.1016/j.ucl.2007.09.012

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  44 in total

1.  Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Authors:  G Theyer; G Kramer; I Assmann; E Sherwood; W Preinfalk; M Marberger; O Zechner; G E Steiner
Journal:  Lab Invest       Date:  1992-01       Impact factor: 5.662

Review 2.  Molecular and cellular pathogenesis of benign prostatic hyperplasia.

Authors:  Keith L Lee; Donna M Peehl
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

3.  Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men.

Authors:  R O Roberts; M M Lieber; T Rhodes; C J Girman; D G Bostwick; S J Jacobsen
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

Review 4.  Benign prostatic hyperplasia: age-related tissue-remodeling.

Authors:  Gerold Untergasser; Stephan Madersbacher; Peter Berger
Journal:  Exp Gerontol       Date:  2005-01-22       Impact factor: 4.032

5.  Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.

Authors:  Gero Kramer; Georg E Steiner; Alessandra Handisurya; Ursula Stix; Andrea Haitel; Birgit Knerer; Alois Gessl; Chung Lee; Michael Marberger
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

6.  Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Authors:  Franco Di Silverio; Cesare Bosman; Monti Salvatori; Luca Albanesi; Laura Proietti Pannunzi; Mauro Ciccariello; Antonio Cardi; Gianfilippo Salvatori; Alessandro Sciarra
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

7.  Prevalence and correlates of prostatitis in the health professionals follow-up study cohort.

Authors:  Mary McNaughton Collins; James B Meigs; Michael J Barry; Elizabeth Walker Corkery; Edward Giovannucci; Ichiro Kawachi
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

8.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Authors:  Gerald Andriole; David Bostwick; Otis Brawley; Leonard Gomella; Michael Marberger; Donald Tindall; Sharon Breed; Matt Somerville; Roger Rittmaster
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

9.  Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.

Authors:  Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger
Journal:  Lab Invest       Date:  2003-08       Impact factor: 5.662

Review 10.  Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.

Authors:  A C Buck
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

View more
  47 in total

Review 1.  Inflammation and benign prostatic hyperplasia: clinical implications.

Authors:  Bilal Chughtai; Richard Lee; Alexis Te; Steven Kaplan
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

2.  Age-related histological and zinc content changes in adult nonhyperplastic prostate glands.

Authors:  Vladimir Zaichick; Sofia Zaichick
Journal:  Age (Dordr)       Date:  2013-07-14

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

4.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

5.  Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

6.  Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation.

Authors:  Xiaohai Wang; Wen-Jye Lin; Kouji Izumi; Qi Jiang; Kuo-Pao Lai; Defeng Xu; Lei-Ya Fang; Tianjing Lu; Lei Li; Shujie Xia; Chawnshang Chang
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

7.  Discovering medical conditions associated with periodontitis using linked electronic health records.

Authors:  Mary Regina Boland; George Hripcsak; David J Albers; Ying Wei; Adam B Wilcox; Jin Wei; Jianhua Li; Steven Lin; Michael Breene; Ronnie Myers; John Zimmerman; Panos N Papapanou; Chunhua Weng
Journal:  J Clin Periodontol       Date:  2013-03-15       Impact factor: 8.728

8.  Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials.

Authors:  Mohammad Bagherniya; Gholamreza Askari; Babak Alikiaii; Saeed Abbasi; Davood Soleimani; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

10.  The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment.

Authors:  Young Kee Kwon; Mi Sun Choe; Kyung Won Seo; Chol Hee Park; Hyuk Soo Chang; Byung Hoon Kim; Chun Il Kim
Journal:  Korean J Urol       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.